ST. LOUIS & SAN DIEGO--(BUSINESS WIRE)--Wugen a clinical-stage biotechnology company developing a pipeline of off-the-shelf cell therapies to treat a broad range of hematological and solid tumor malignancies, today announced that management will participate in the upcoming Virtual Jefferies London Healthcare Conference set to take place November 16 - 19, 2021. The presentation will be available to registered conference attendees for on-demand viewing on Thursday, November 18 at 8:00 a.m. GMT (3:00 a.m. ET).

About Wugen

Wugen, Inc., is a clinical-stage biotechnology company developing a pipeline of off-the-shelf memory NK and CAR-T cell therapies to treat a broad range of hematological and solid tumor malignancies. Memory NK cells are hyper-functional, long-lasting immune cells that have evolved to attack cancer and respond to infection. Wugen is harnessing the power of this rare cell population by using its proprietary technologies to create WU-NK-101, currently in clinical development for acute myelogenous leukemia (AML). Wugen is also advancing WU-CART-007, currently in development for T-cell acute lymphoblastic leukemia (T-ALL). For more information, please visit www.wugen.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20211110005246/en/